Global Digital Breast Tomosynthesis Equipment Market Size

Digital Breast Tomosynthesis Equipment Market Analysis

The Global Digital Breast Tomosynthesis Equipment Market size is estimated at USD 3.34 billion in 2024, and is expected to reach USD 6.37 billion by 2029, growing at a CAGR of 13.83% during the forecast period (2024-2029).

COVID-19 outbreak has significantly impacted the Digital Breast Tomosynthesis Equipment Market during the pandemic period. The pandemic resulted in substantial reductions in breast cancer screening, cancer management visits, and cancer procedures across the globe. For instance, a study published in the Journal of the American College of Radiology in June 2022 stated that cancer diagnoses dropped by nearly 50% in the peak-pandemic period and have not entirely rebounded to the pre-COVID rate. The strict lockdown and the policies led to the relocation of medical healthcare providers and material resources, which led the healthcare providers to focus primarily on this abrupt pandemic emergency, thereby postponing other non-emergency medical services such as digital breast tomosynthesis. However, the relaxation of the lockdown restrictions and the resumption of cancer diagnostics during the post-pandemic period are expected to contribute to the market's growth.

The growth factors expected to drive the market are the increasing prevalence of breast cancer worldwide, technological advancements in the field of breast imaging, and rising awareness about the use of digital breast tomosynthesis (DBT). The increasing prevalence of breast cancer cases is expected to drive the demand for advanced diagnosis, fueling the studied market. For instance, the article published in MDPI in July 2022 mentioned that 45.4% of breast cancer cases were diagnosed in Asia in 2021. Additionally, the Breast Cancer Organization data published in August 2022 mentioned that breast cancer is the most common cancer globally, accounting for 12.5% of cancer cases annually. The report also mentioned that it is estimated that about 30% of all diagnosed cancer in women might be breast cancer in 2022. The rising prevalence of breast cancer is expected to drive the demand for digital breast tomosynthesis equipment owing to the advanced diagnosis, thereby contributing to the market's growth.

On the other hand, the increasing product launches by various key market players is also expected to contribute to the market's growth over the forecast period. For instance, in August 2021, FUJIFILM Medical Systems launched its ASPIRE Cristalle mammography system with Digital Breast Tomosynthesis (DBT) that offers ScreenPoint Medical's new, US FDA-cleared Transpara powered by Fusion Artificial Intelligence (AI) for 2D and 3D mammography in the United States. Moreover, rising awareness campaigns by various organizations working towards spreading awareness about breast cancer are expected to play a vital role in the market's growth. For instance, in October 2021, the Pink Bot breast cancer awareness campaign was initiated with a chat module integrated to answer queries on breast cancer, the latest initiative from Dr. P Guhan and his team to raise awareness of it. Similarly, in May 2022, Mount Sinai Health System initiated Mammogram May to empower women to take charge of their breast health by scheduling an annual mammogram. The goals of the campaign are to raise awareness of the importance of mammography in early breast cancer detection and treatment and to address a decline in breast screenings worsened by the pandemic.

Thus, due to the aforesaid mentioned reasons, the market is expected to show significant growth over a forecast period. However, the high costs of the systems and side effects associated with radiation exposure may slow down its growth over the forecast period.